Skip to Main Content

Paper Details

Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
Leukemia
16
2021
ALL, CRLF2, CRLF2-rearranged Ph-like ALL, CRLF2-rearranged Ph-like ALL xenografts, JAK, L-asparaginase, Ph, Ph-, Ph-like ALL, Ph-like acute lymphoblastic leukemia, Philadelphia, Philadelphia chromosome-like acute lymphoblastic leukemia, STAT, dexamethasone, patient, ruxolitinib, vincristine
Author NameAffiliation
Kathryn EvansChildren's Cancer Institute
Chelsea MayohChildren's Cancer Institute
Mark J Raftery
Marc R Wilkins
Marc R Wilkins
Michelle HaberChildren's Cancer Institute
Glenn M MarshallChildren's Cancer Institute
Glenn M MarshallKids Cancer Centre, Sydney Children's Hospital
Richard B LockChildren's Cancer Institute
  • 1 - 9

Datasets

Release 1.2